… Citation3 Escitalopram is a single S-enantiomer of citalopram… on a 12-month open-label
study of 486 patients treated with … of CYP2C19 poor metabolizers (PMs) within the Chinese …

… [39] had conducted a conventional bioequivalence study in 24 healthy CYP2C19 … branded
citalopram 20 mg tablets: an open-label, randomized-sequence, two-period crossover study …

… pharmacokinetic determinants, including extent of absorption, body … metabolized by
CYP2C9, CYP2C19, or CYP2D6, and … were > 1, ranging from 1.04 (citalopram) to 2.94 (omeprazole), …

… study, the pharmacokinetics of the transdermal CTH delivery system were analyzed in rabbits.
The results showed that the system had good absorption … dosage range (20 mg to 40 mg) […

… basic indexes, we compared the association between different … three phenotypes, namely
extensive metabolizer, CYP2C19*1/*… genetic polymorphism into population pharmacokinetics. …

… -blind randomised cross-over design. Relative to placebo, … doses of atomoxetine (60 mg),
citalopram (30 mg), and placebo in a … whether individual differences in the citalopram effect on …

… , pharmacokinetics and the … Citalopram’s manufacturer suggests that potent inhibitors of
CYP3A4 and potent inhibitors of CYP2C19 such as omeprazole may inhibit the metabolism of …

… An open label, monocentric, randomized, 2x2 crossover study in 36 … determination of
citalopram enantiomers and application to a pharmacokinetic evaluation of generic and reference …

… branded citalopram 20 mg tablets: an open-label, randomized-sequence, two-period crossover
study in healthy Chinese CYP2C19 extensive metabolizers [J]. Clin Drug Investig, 2013, …

… branded citalopram 20 mg tablets: an open-label, randomized-sequence, two-period crossover
study in healthy Chinese CYP2C19 extensive metabolizers [J]. Clin Drug Investig, 2013, …